The dynamic between pulmonary hypertension (PH) and COVID-19 has been under investigation since 2020, early in the pandemic. Although the pathophysiology of PH has been well-studied, new discoveries regarding the multisystemic effects of COVID-19 are still being uncovered. The cardiopulmonary effects of COVID-19 have led investigators to inquire about the interplay between these 2 conditions. Several factors are suggested to contribute to an increased risk of developing PH after infection with SARS-CoV-2. This includes cytokine storm, acute respiratory distress syndrome, and fibrotic changes seen in post-COVID-19 lung disease. Additionally, it has been proposed that certain medications used to treat PH may be applied to patients suffering from the cardiopulmonary complications of COVID-19. This review will focus on the interplay between COVID-19 and PH, with a special focus on the risk of developing PH after SARS-CoV-2 infection and the outcomes of patients with preexisting PH who are diagnosed with COVID-19. The potential benefits of utilizing off-label PH medications for COVID-19 patients will also be discussed.

中文翻译：

---

COVID-19 和肺动脉高压：一个有趣的动态。

自 2020 年大流行初期以来，人们一直在研究肺动脉高压 (PH) 和 COVID-19 之间的动态关系。尽管 PH 的病理生理学已得到充分研究，但有关 COVID-19 多系统影响的新发现仍在被发现。COVID-19 对心肺的影响促使研究人员探究这两种情况之间的相互作用。研究表明，有几个因素会导致感染 SARS-CoV-2 后患 PH 的风险增加。这包括细胞因子风暴、急性呼吸窘迫综合征以及 COVID-19 后肺部疾病中出现的纤维化变化。此外，有人建议某些用于治疗肺动脉高压的药物可用于患有 COVID-19 心肺并发症的患者。本综述将重点关注 COVID-19 和 PH 之间的相互作用，特别关注 SARS-CoV-2 感染后发生 PH 的风险以及诊断患有 COVID-19 的既往 PH 患者的结果。还将讨论对 COVID-19 患者使用标签外 PH 药物的潜在好处。